公开(公告)号：US12227504B2

公开(公告)日：2025-02-18

申请号：US18100992

申请日：2023-01-24

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Fabian Dey ,  Annick Goergler ,  Bernd Kuhn ,  Roger Norcross ,  Stephan Roever ,  Philipp Schmid

IPC: C07D471/10 ,  A61K31/438 ,  C07D519/00

Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

公开(公告)号：US20230416251A1

公开(公告)日：2023-12-28

申请号：US18100992

申请日：2023-01-24

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Fabian Dey ,  Annick Goergler ,  Bernd Kuhn ,  Roger Norcross ,  Stephan Roever ,  Philipp Schmid

IPC: C07D471/10 ,  C07D519/00

CPC classification number: C07D471/10 ,  C07D519/00

Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

公开(公告)号：US20230145336A1

公开(公告)日：2023-05-11

申请号：US18084380

申请日：2022-12-19

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Martin Duplessis ,  Mark E. Fitzgerald ,  Victoria Garza ,  Andrew Charles Good ,  Katrina L. Jackson ,  Yanke Liang ,  Moses Moustakim ,  Morgan Welzel O'Shea ,  Gesine Kerstin Veits ,  Jeremy L. Yap ,  Robert T. Yu ,  Cosimo Dolente ,  David Stephen Hewings ,  Daniel Hunziker ,  Bernd Kuhn ,  Piergiorgio Francesco Tommaso Pettazzoni ,  Fabienne Ricklin ,  Claus Riemer ,  Juergen Wichmann

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.

公开(公告)号：US11584748B2

公开(公告)日：2023-02-21

申请号：US17072896

申请日：2020-10-16

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Fabian Dey ,  Annick Goergler ,  Bernd Kuhn ,  Roger Norcross ,  Stephan Roever ,  Philipp Schmid

IPC: C07D471/10 ,  A61K31/438 ,  C07D519/00

Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

公开(公告)号：US20210032245A1

公开(公告)日：2021-02-04

申请号：US17072896

申请日：2020-10-16

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Fabian Dey ,  Annick Goergler ,  Bernd Kuhn ,  Roger Norcross ,  Stephan Roever ,  Philipp Schmid

IPC: C07D471/10 ,  C07D519/00

Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

公开(公告)号：US20200308171A1

公开(公告)日：2020-10-01

申请号：US16903237

申请日：2020-06-16

Applicant: Hoffmann-La Roche Inc. ,  C4 Therapeutics, Inc.

Inventor： Georg Jaeschke ,  Bernd Kuhn ,  Antonio Ricci ,  Daniel Rueher ,  Sandra Steiner ,  Yvonne Alice Nagel ,  Martin Duplessis ,  Kiel Lazarski ,  Yanke Liang

IPC: C07D471/04

Abstract: Present invention provides bifunctional compounds that comprise an E3 Ubiquitin Ligase moiety that is linked to a moiety that inhibit EGFR, where the target protein can be proximate to the ubiquitin ligase to effect degradation of said protein. Present compounds are useful for the treatment of various cancers.